Ligand validation:3ASO

CDL: CARDIOLIPIN

CDL is a Ligand Of Interest in 3ASO designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3ASO_CDL_C_270	4%	33%	0.361	0.747	1.36	1.3	13	13	25	0	100%	1
3ASO_CDL_P_1270	4%	31%	0.357	0.732	1.37	1.36	12	13	21	0	100%	1
3ASO_CDL_G_269	2%	32%	0.356	0.606	1.38	1.31	12	9	21	0	100%	1
3ASO_CDL_T_1269	1%	34%	0.359	0.555	1.36	1.26	12	7	31	0	100%	1
9IKG_CDL_L_101	53%	71%	0.147	0.919	0.41	0.7	-	4	4	0	94%	1
9KUM_CDL_L_101	52%	72%	0.144	0.913	0.45	0.63	-	2	6	0	94%	1
9IKF_CDL_L_101	51%	72%	0.152	0.916	0.39	0.69	-	2	3	0	94%	1
9KUL_CDL_L_101	50%	73%	0.154	0.916	0.42	0.62	-	2	10	0	94%	1
9KUK_CDL_L_101	49%	74%	0.153	0.911	0.4	0.6	-	2	7	0	94%	1
9GCX_CDL_C_504	62%	68%	0.143	0.934	0.43	0.79	-	2	16	0	100%	1
7C52_CDL_M_406	55%	46%	0.118	0.886	0.93	1.14	4	7	7	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.